Chad Stephen Boomershine MD PhD (He/Him)
Crystal Related
Clinical Research Medical Director, Amgen Inc.
Join to view full profile
One Amgen Center DriveNewbury Park, CA 91320
Phone+1 937-988-1015
Dr. Boomershine is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Chad Boomershine is Clinical Research Medical Director Rheumatology, Rare Disease at Amgen, one of the world's leading independent biotechnology companies, developing new treatments for patients with rheumatic diseases. Dr. Boomershine received his MD and PhD degrees from The Ohio State University and completed an Internal Medicine residency, Rheumatology Fellowship, and post-doctoral research training at Vanderbilt University.
Education & Training
Vanderbilt University Medical CenterFellowship, Rheumatology, 2004 - 2008- Vanderbilt University Medical CenterResidency, Internal Medicine, 2002 - 2004
Ohio State University College of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2022 - 2028
NM State Medical License 2022 - 2026
IL State Medical License 2022 - 2026
AZ State Medical License 2022 - 2025
NJ State Medical License 2022 - 2025
NC State Medical License 2022 - 2025
NV State Medical License 2022 - 2025
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Pain Medicine
- National Board of Physicians and Surgeons Rheumatology
American Board of Pain MedicineBoard Certified Pain Medicine- Association of Clinical Research ProfessionalsCertified Principal Investigator
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- 29 citationsA Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia.Chad S. Boomershine, Todd A. Koch, David Morris
Rheumatology and Therapy. 2018-06-01 - 67 citationsFibromyalgia: The Prototypical Central Sensitivity SyndromeChad S Boomershine
Current Rheumatology Reviews. 2015-07-31 - 29 citationsTime course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohortLiana D. Castel, Katherine E Hartmann, Ingrid A. Mayer, Benjamin R. Saville, JoAnn Alvarez
Cancer. 2013-07-01
Grant Support
- Mechanisms Of Dendritic Cell Tolerance In Autoimmune PancreatitisNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
Professional Memberships
- Member
- Tennessee Rheumatology SocietyPresident
- Clinical Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: